IP Library › Granted Patent US 10,150,793
Granted Patent B2
US 10,150,793 · App. 14/118,420 · Granted Dec 11, 2018

Antagonists of CB1 receptor

Inventors: Pier Vincenzo Piazza (Bordeaux, FR); Monique Vallee (Bordeaux, FR); Giovanni Marsicano (Bordeaux, FR); Francois-Xavier Felpin (Nantes, FR); Luigi Bellocchio (Bordeaux, FR); Daniela Cota (Bordeaux, FR); Jean-Michel Revest (Bordeaux, FR); Sergio Vitiello (Bordeaux, FR); Umberto Spampinato (Bordeaux, FR); Rafael Maldonado (Barcelone, ES)
Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale); UNIVERSITE DE BORDEAUX
C07J7/0075A61K31/57C07J5/0015C07J7/0005C07J7/007C07J7/0015C07J7/0045C07J11/00C07J13/005C07J13/007C07J31/006C07J41/005C07J41/0011C07J41/0027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,150,793
App. No.
14/118,420
Granted
Dec 11, 2018
Kind
B2
Abstract

The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.

Claims (2)

1. A pregnenolone derivative wherein said pregnenolone derivative is 17α-Benzyl-3β-fluoropregnenolone, 17α-Benzyl-3β-benzyloxypregnenolone, 3β-Benzyloxy-17α-methylpregnenolone, 17α-Benzylpregnenolone, 3β-Methoxy-17α-methylpregnenolone, 17α-Allyl-3β-methoxypregnenolone or 17α-Benzyl-3β-methoxypregnenolone.

2. A pharmaceutical composition comprising a pregnenolone derivative according to claim 1 and a pharmaceutically acceptable carrier.

Assignments (3)
CHANGE OF NAME Recorded Jul 15, 2014
From: UNIVERSITE DE BORDEAUX I; UNIVERSITE DE BORDEAUX II VICTOR SEGALEN
To: UNIVERSITE DE BORDEAUX
Reel/Frame 033312/0569 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF ASSIGNEE SHOULD BE UNIVERSITE DE BORDEAUX I PREVIOUSLY RECORDED ON REEL 032303 FRAME 0606. ASSIGNOR(S) HEREBY CONFIRMS THE SPELLING OF ASSIGNEE WAS ORIGINALLY UNIVERSITE DE BORDEAUX. Recorded Apr 9, 2014
From: PIAZZA, PIER VINCENZO; VALLEE, MONIQUE; MARSICANO, GIOVANNI; FELPIN, FRANCOIS-XAVIER; BELLOCCHIO, LUIGI; COTA, DANIELA; REVEST, JEAN-MICHEL; VITIELLO, SERGIO; SPAMPINATO, UMBERTO; MALDONADO, RAFAEL
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DE BORDEAUX I; UNIV DE BORDEAUX II VICTOR SEGALEN
Reel/Frame 032643/0594 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2014
From: PIAZZA, PIER VINCENZO; VALLEE, MONIQUE; MARSICANO, GIOVANNI; FELPIN, FRANCOIS-XAVIER; BELLOCCHIO, LUIGI; COTA, DANIELA; REVEST, JEAN-MICHEL; VITIELLO, SERGIO; SPAMPINATO, UMBERTO; MALDONADO, RAFAEL
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DE BORDEAUX; UNIV DE BORDEAUX II VICTOR SEGALEN
Reel/Frame 032303/0606 →
Priority Claims (1)
EP 11305625 · May 20, 2011 · regional
Continuity (1)
Related Publication 20140200200A1 · Jul 17, 2014
Cited By (1)
US 12,583,884